Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice

Archives of Virology

Volumn 156, Issue 5, 2011, Pages 753-758

  Huang, Hainan ^a,b   Xiao, Shaobo ^c   Qin, Junling ^a,b   Jiang, Yunbo ^c   Yang, Songtao ^b   Li, Tingting ^c   Gao, Yuwei ^b   Li, Zilong ^c   Li, Tiansong ^b   Su, Xiuchan ^c   Ruan, Yang ^b   Xu, Fengqin ^c   Wang, Hualei ^a,b   Chen, Huanchun ^c   Xia, Xianzhu ^b  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; GLYCOPROTEIN; GLYCOPROTEIN G, RABIES VIRUS; NEUTRALIZING ANTIBODY; RABIES VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL; ARTICLE; BACULOVIRUS; BLOOD; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; MOUSE; RABIES VIRUS; VACCINATION; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACULOVIRIDAE; DRUG CARRIERS; FEMALE; GENETIC VECTORS; GLYCOPROTEINS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED ICR; RABIES VACCINES; RABIES VIRUS; VACCINATION; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS;

CYTOMEGALOVIRUS; MAMMALIA; MUS; RABIES VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 79955147980     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-010-0909-4     Document Type: Article

References (49)

1. Conzelmann KK, Cox JH, Schneider LG et al (1990) Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19 [J]. Virology 175(2): 485-499.
2. Cox JH, Dietzschold B, Schneider LG (1977) Rabies virus glycoprotein II: biological and serological characterization. Infect Immunol 16: 754-759.
3. Dietzschold B, Wunner WH, Wiktor TJ et al (1983) Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci USA 80: 70-74.
4. Morimoto K, McGettigan JP, Foley HD et al (2001) Genetic engineering of live rabies vaccines. Vaccine 19: 3543-3551.
5. Wiktor T, Gyorgy E, Schlumberger D et al (1973) Antigenic properties of rabies virus components. J Immunol 110: 269-276.
6. Thoulouze MI, Lafage M, Mantano-Hirose JA et al (1997) Rabies virus infects mouse and human lymphocytes and induces apoptosis. J Virol 71: 7372-7380.
7. Tuffereau C, Lebblois H, Benejean J et al (1989) Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology 172: 206-212.
8. Gaudin Y, Tuffereau C, Segretain D et al (1991) Reversible conformational changes and fusion activity of rabies virus glycoprotein. J Virol 65: 4853-4859.
9. Bahloul C, Taieb D, Diouani MF et al (2006) Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine 24: 1063-1072.
10. Ray NB, Ewalt LC, Lodmell DL (1997) Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 15: 892-895.
11. Lodmell DL, Ray NB, Parnell MJ et al (1998) DNA immunization protects nonhuman primates against rabies virus. Nat Med 4: 949-952.
12. Perrin P, Jacob Y, Aguilar-Setien A et al (1999) Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 18: 479-486.
13. Lodmell DL, Ewalt LC (2001) Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 19: 2468-2473.
14. Lodmell DL, Parnell MJ, Bailey JR et al (2002) Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers. Vaccine 20: 2221-2228.
15. Lodmell DL, Parnell MJ, Weyhrich JT et al (2003) Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody. Vaccine 21: 3998-4002.
16. Fischer L, Minke J, Dufay N et al (2003) Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine 21: 4593-4596.
17. Cupillard L, Juillard V, Latour S et al (2005) Impact of plasmid supercoiling on the efficacy of a rabies DNA vaccine to protect cats. Vaccine 23: 1910-1916.
18. Tesoro-Cruz E, Calderón-Rodríguez R, Hernández-González R et al (2008) Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus. Vet Res 39: 16.
19. Saxena S, Dahiya SS, Sonwane AA et al (2008) A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine 26: 6592-6601.
20. Tesoro Cruz E, Feria Romero IA, López Mendoza JG et al (2008) Efficient post-exposure prophylaxis against rabies by applying a four-dose DNA vaccine intranasally. Vaccine 26: 6936-6944.
21. LuckowVA MD (1988) Signals important for high-level expression of foreign genes in Autographa californica nuclear polyhedrosis virus expression vectors. Virology 167: 56-71.
22. Hofmann C, Sandig V, Jennings G et al (1995) Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA 92: 10099-10103.
23. Carbonell LF, Klowden MJ, Miller LK (1985) Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells. J Virol 56: 153-160.
24. Tjia ST, zu Altenschildesche GM, Doerfler W (1983) Autographa californica nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass cultures of mammalian cells. Virology 125: 107-117.
25. Volkman LE, Goldsmith PA (1983) In vitro survey of Autographa californica nuclear polyhedrosis virus interaction with nontarget vertebrate host cells. Appl Environ Microbiol 45: 1085-1093.
26. Aoki H, Sakoda Y, Jukuroki K et al (1999) Induction of antibodies in mice by a recombinant baculovirus expressing pseudorabies virus glycoprotein B in mammalian cells. Vet Microbiol 68: 197-207.
27. Lu L, Yu L, Kwang J (2007) Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. Biochem Biophys Res Commun 358(2): 404-409.
28. Strauss R, Huser A, Ni S et al (2007) Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol Ther 15: 193-202.
29. Facciabene A, Aurisicchio L, La MN (2004) Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol 78: 8663-8672.
30. Fan H, Xiao S, Fang L et al (2007) Efficient transduction of porcine kidney cells with pseudotype baculovirus. J Huazhong Agri Univ 26: 478-481.
31. Xiao S, Chen H, Fang L et al (2004) Comparison of immune responses and protective efficacy of suicidal DNA vaccine and conventional DNA vaccine encoding glycoprotein C of pseudorabies virus in mice. Vaccine 22: 345-351.
32. Fan H, Pan Y, Fang L et al (2008) Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. J. Virol. Methods 150: 21-26.
33. Luckow VA, Lee SC, Barry GF et al (1993) Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. J Virol 67(8): 4566-4579.
34. Hu YC (2005) Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacol Sin 26: 405-416.
35. Kost TA, Condreay JP, Jarvis D (2005) Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 23: 567-575.
36. Heimpela AM, Buchananb LK (1967) Human feeding tests using a nuclear-polyhedrosis virus of Heliothis zea. J Invertebr Pathol 9(1): 55-57.
37. Ignoffo CM, Heimpe AM (1965) The nuclear-polyhedrosis virus of Heliothis zea (Boddie) and Heliothis virescens (Fabricius): v. Toxicity-pathogenicity of virus to white mice and guinea pigs. J Invert Pathol 7(3): 329-340.
38. Barsoum J, Brown R, McKee M et al (1997) Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein. Hum Gene Ther 8(17): 2011-2018.
39. Tani H, Limn CK, Yap CC et al (2003) In vitro and in vivo gene delivery by recombinant baculoviruses. J Virol 77: 9799-9808.
40. Pieroni L, Maione D, La Monica N (2001) In vivo gene transfer in mouse skeletal muscle mediated by baculovirus vectors. Hum Gene Ther 12: 871-881.
41. Babiuk S, van Drunen Littel-van den Hurk S, Babiuk LA (2006) Delivery of DNA vaccines using electroporation. Methods Mol Med 127: 73-82.
42. Long BR, Michaelsson J, Loo CP et al (2008) Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol 15: 120-130.
43. Johnson N, Cunningham AF, Fooks AR (2010) The immune response to rabies virus infection and vaccination. Vaccine 28: 3896-3901.
44. Hooper DC, Morimoto K et al (1998) Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J. Virol 72: 3711-3719.
45. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11(4): S63-S68.
46. Kanzler H, Barrat FJ, Hessel EM et al (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med 13: 552-559.
47. Schijns VE (2000) Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12: 456-463.
48. Hoebe K, Janssen E, Beutler B (2004) The interface between innate and adaptive immunity. Nat Immunol 5: 971-974.
49. Newman KC, Riley EM (2007) Whatever turns you on: accessory-cell dependent activation of NK cells by pathogens. Nat Rev Immunol 7: 279-291.